AbCelex Technologies to Present at VetHealth Global 2013

TORONTO, ONTARIO June 10, 2012 | AbCelex Technologies to Present at VetHealth Global 2013
The International Animal Health and Nutrition Business Conference

– AbCelex Technologies announced today that the Company has been invited to present at the upcoming VetHealth Global 2013 conference to be held June 10-12 in Princess Edward Islands, Canada.

AbCelex has been selected for the Innovation in Animal Health and Nutrition as one of the top 10 emerging companies who are bringing exciting new technologies to the marketplace to present at this global conference.

VetHealth Global has consistently attracted a top drawer group of multinational companies and early stage businesses that come together in an informal setting to share new research and product concepts, identify investment opportunities, establish new sales channels, and discuss global animal health issues and trends. Delegates from North America, the U.K., China, Switzerland, Brazil, and Israel will participate in this year’s Conference.

Information on this event can be found on the conference website: https://www.vethealthglobal.com/emerging_companies_presentations.php

About VetHealth Global 2013

VetHealth Global is North America’s Premier International Animal Health & Nutrition Business Conference. Over 150 delegates from animal health and nutrition companies and support organizations from around the world will be in Prince Edward Island, Canada from June 10 – 12th for VetHealth Global 2013. Since 2007, VetHealth Global has received recognition for its stellar list of participating presenters, innovative emerging companies, business-to-business partnering program, and top-rated networking events. For more information, visit https://www.vethealthglobal.com.

About AbCelex Technologies Inc.

AbCelex Technologies Inc. is a privately owned Canadian biotechnology company committed to the discovery and development of innovative technologies for food safety applications. AbCelex’s current efforts are catered towards the development and commercialization of diagnostic and novel feed additive products for food animal health and food safety. For more information, visit www.abcelex.com.

Enquiries:

For further information, please contact: ir@abcelex.com

AbCelex Technologies to Participate at Two Upcoming Conferences

TORONTO, ONTARIO February 21, 2012 | AbCelex Technologies Inc. announced today that the Company will be participating at two upcoming international conferences:

  • 10th Annual BioPartnering North America, February 26-28, 2012, Vancouver Convention Centre;
  • GLOBE 2012, 12th Biennial Conference & Trade Fair on Business & the Environment, March 14–16, 2012, Vancouver Convention Centre.

About AbCelex Technologies Inc.

AbCelex Technologies Inc. is a privately owned Canadian biotechnology company committed to the discovery and development of innovative technologies for the diagnosis and treatment of variety of illnesses including cancer and infectious diseases. Our current efforts are catered towards the development and commercialization of high avidity single domain antibody (sdAb)-based diagnostic and food safety products to help patients worldwide with the best care possible. For more information, visit www.abcelex.com.

About BioPartnering North America (BPN)

BioPartnering North America 2012 (BPN) brings together senior executives from venture capital firms, major pharmaceutical companies, academic institutions and biotechnology companies of every size from mature to start-up. Now in its 10th year of partnering & dealmaking, BPN is focusing on the Pacific Rim. The strategy is to build on close ties with industry leaders in the Pacific Rim to create a unique opportunity for the U.S., Canada, and Europe to meet leading life science companies from Asia.

About Globe

Having been around since 1990, GLOBE is known as the quintessential gathering of global senior business and government representatives who meet to network and to advance the issues at the nexus of global business and sustainability agendas.

Enquiries:

For further information, please contact:
ir@abcelex.com

Research Collaboration and Commercialization Agreement with the Carton Group

TORONTO, ONTARIO February 2, 2012 | AbCelex Technologies Announces Research Collaboration and Commercialization Agreement with the Carton Group

– AbCelex Technologies Inc. is pleased to announce a strategic collaboration agreement with the Carton Group.
According to the signed agreement terms, AbCelex and Carton will jointly research and develop products effective against Campylobacter jejuni. AbCelex’s proprietary antibody-based platform technology can be a substantial solution worldwide to help prevent or significantly reduce food-borne illnesses.

“I am extremely pleased for this cooperation between AbCelex and Carton where we can contribute to the reduction of C. jejuni infections and other harmful microbes which continue to be pervasive throughout our food supply chain”, said Dr. Saeid Babaei, Chairman of the Board at AbCelex. “This collaboration will provide AbCelex with an opportunity to strengthen its presence in the food safety market in partnership with one of the world’s largest food companies in the rapidly growing and profitable segment”.

“I am very excited about the opportunity to join AbCelex research team in investigating innovative technologies to reduce Campylobacter infection in our food supply as consumers, now more than ever, are vigilant when it comes to food safety,” said Mr. Vincent Carton, Managing Director at Carton Group. “Adding innovative and effective products to our portfolio is an important aspect of our business strategy in ensuring that our birds are raised to the highest food safety and animal care standards. We are firmly behind the wheel in the drive for innovation and growth in our industry.”

According to the Centers for Disease Control and Prevention (CDC), Campylobacter, primarily C. jejuni, is the third leading cause of death from foodborne infections in the world. In the United States alone, it affects nearly 2.4 million people, causes an estimated 58,000 illnesses and 200 deaths, and costs companies millions of dollars in recall losses in the U.S. each year. A substantial portion of the illnesses and deaths are associated with meat and poultry products.

A recent survey of Canadians conducted by BrandTrust found that food safety now ranks virtually equal to freshness when considering purchasing processed meats – 94% of respondents ranked food freshness as the most influential factor, with 92% also ranking food safety.

About AbCelex Technologies Inc.

AbCelex Technologies Inc. is a privately owned Canadian biotechnology company committed to the discovery and development of innovative technologies for the diagnosis and treatment of variety of illnesses including cancer and infectious diseases. Our current efforts are catered towards the development and commercialization of high avidity single domain antibody (sdAb)-based diagnostic and food safety products to help patients worldwide with the best care possible. The Company is looking at opportunities in the diagnostic market in addition to developing products for the animal health market that could help to prevent food borne infection at the animal source. For more information, visit www.abcelex.com.

About Carton Group

Carton Group with its Manor Farm brand is one of the oldest family companies in Ireland dating back to 1775 and now in its 8th generation. Today, Carton is Ireland’s largest integrated chicken processor, based in Shercock, Co Cavan, where it processes 800,000 birds per week and produces 130,000 tonnes of chicken feed a year. Carton employs over 650 people throughout the year and 750 during the summer months. In addition to this the company has 150 breeder, broiler and free-range farmers and gives indirect employment to many more throughout the 26 counties. The company recorded a turnover of €205 million in 2011 and the payroll costs came to €22 million.

About Campylobacter

Campylobacter is the cause of enteric infections that can be severe enough to cause death or serious neurological damage. It is a major public health issue with a considerable socio-economic impact. Foods are a significant risk factor for human campylobacteriosis, and the infectious dose seems to be very low. Poultry-based foods are assumed to be the primary source of campylobacteriosis, with the main routes of infection being the ingestion of inadequately cooked meat (primarily poultry) and cross-contamination.

Enquiries:

For further information, please contact:
Dr. Saeid Babaei
ir@abcelex.com